Evidence map›Paper›PMID 34156448›Full record

ArticleDatabase : the journal of biological databases and curation2021

ReMeDy: a platform for integrating and sharing published stem cell research data with a focus on iPSC trials.

Kirill Borziak, Irena Parvanova, Joseph Finkelstein

Abstract read
In one paragraph

Article in Database : the journal of biological databases and curation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Towards an Open-Source Platform to Harmonize and Share Research Results from COVID-19 Interventional and Observational Studies.AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science · 2023
    Article
  2. Article
  3. A Web-based Platform to Share Harmonized Results from COVID-19 Clinical Studies.AMIA ... Annual Symposium proceedings. AMIA Symposium · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Kirill BorziakCenter for Biomedical and Population Health Informatics, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, Icahn L2-36, New York, NY 10029, USA.ORCID 0000-0001-8126-9690
Irena ParvanovaCenter for Biomedical and Population Health Informatics, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, Icahn L2-36, New York, NY 10029, USA.
Joseph FinkelsteinCenter for Biomedical and Population Health Informatics, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, Icahn L2-36, New York, NY 10029, USA.

Funding

Conduits: Mount Sinai Health System Translational Science HubUL1TR004419 · NCATS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Rosalind J Wright · 2022 to 2026
$46.4M
MSHS Translational Science HubUL1TR001433 · NCATS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI WRIGHT, ROSALIND J · 2015 to 2019
$26.6M
Enhancing the Development of New Regenerative Medicine Therapies:Proposal to Build a Robust Clinical Research Development and Data HubOT2HL147606 · NHLBI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI FINKELSTEIN, JOSEPH E · 2018 to 2019
$1.8M
NCATS NIH HHS UL1 TR001433NCATS NIH HHS UL1 TR004419NHLBI NIH HHS OT2 HL147606
6 · The paper itself

Abstract

abstractRecent regenerative medicine studies have emphasized the need for increased standardization, harmonization and sharing of information related to stem cell product characterization, to help drive these innovative interventions toward public availability and to increase collaboration in the scientific community. Although numerous attempts and numerous databases have been made to manage these data, a platform that incorporates all the heterogeneous data collected from stem cell projects into a harmonized project-based framework is still lacking. The aim of the database, which is described in this study, is to provide an intelligent informatics solution that integrates comprehensive characterization of diverse stem cell product characteristics with research subject and project outcome information. In the resulting platform, heterogeneous data are validated using predefined ontologies and stored in a relational database, to ensure data quality and ease of access. Testing was performed using 51 published, publically available induced pluripotent stem cell projects conducted in clinical, preclinical and in-vitro evaluations. Future aims of this project include further increasing the database size to include all published stem cell trials and develop additional data visualization tools to improve usability. Our testing demonstrated the robustness of the proposed platform, by seamlessly harmonizing diverse common data elements, and the potential of this platform for driving knowledge generation from the aggregation and harmonization of these diverse data. DATABASE URL: https://remedy.mssm.edu/.

Indexed as

Induced Pluripotent Stem CellsStem Cell ResearchDatabases, FactualPublications

Identifiers

PMID34156448
PMCPMC8218701

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.